SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
NCT ID: NCT04596579
Last Updated: 2022-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1135 participants
OBSERVATIONAL
2020-10-17
2021-07-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
NCT04579588
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT04794829
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
NCT05078905
Impact of FLU Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses
NCT06824779
Dissecting Human Immune Responses to Infection with Influenza or SARS-CoV-2
NCT06848309
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants age 18-34
Up to 300 participants age 18-34 who received an invitation by mail and are free of fever at time of interview.
SARS-CoV-2 Antibody Analysis
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Weck-cel Swab Collection
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Web Based Questionnaire
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Participants age 35-54
Up to 300 Participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
SARS-CoV-2 Antibody Analysis
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Weck-cel Swab Collection
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Web Based Questionnaire
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Participants age 55-64
Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
SARS-CoV-2 Antibody Analysis
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Weck-cel Swab Collection
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Web Based Questionnaire
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Participants 65 and over
Up to 300 participants age 35-54 who received an invitation by mail and are free of fever at time of interview.
SARS-CoV-2 Antibody Analysis
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Weck-cel Swab Collection
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Web Based Questionnaire
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SARS-CoV-2 Antibody Analysis
10 ml of blood will be drawn for antibody analysis. Participants who test SARCS-CoV-2 positive will be invited to participate in follow-up antibody testing at 4 weeks and at 3 months.
Weck-cel Swab Collection
A Weck-cel swab will be used to collect secretions from the mucosal epithelium
Web Based Questionnaire
A brief web enabled questionnaire will be administered to collect information related to demographics, SARS-CoV-2 exposure history, past symptoms, comorbidities associates with increased infection and disease risk, as well as immunosuppression status and use to immunosuppressive medications.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
* Currently not exhibiting symptoms of SARS-CoV-2 infection
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anna R Giuliano, PhD
Role: PRINCIPAL_INVESTIGATOR
Moffitt Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moffitt Cancer Center
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCC-20635
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.